tbuckley/cabot-search huggingface dataset:
Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
Authors: Evan Carl White, Kelly Erickson, Alex Aleshin, Winston Wei Lien, Aroor R. Rao
Journal: Journal of Clinical Oncology (2013)

e15001 Background: Concurrent chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and mitomycin-C (MMC) is standard treatment for squamous cell carcinoma of the anal canal. Randomized clinical trials in Europe have used 1 cycle MMC, while American studies use 2 cycles. This study sought to determine any difference in treatment outcomes between patients treated with either 1 or 2 cycles of concurrent MMC. Methods: 217 consecutive patients were treated definitively with CRT from 2003 to 2012 in an integrated health system. All patients received radiotherapy at a single regional facility. Concurrent chemotherapy regimen depended on the referring provider’s practice, and consisted of 2 cycles 5-FU (1,000mg/m 2 /day on days 1-4 and 29-32), along with MMC (10mg/m 2 ), given on either day 1 alone (n=154), or days 1 and 29 (n=63). Outcomes were progression-free (PFS), cancer-specific (CSS), overall (OS), and colostomy-free survival (CFS), as well as acute toxicity criteria. Toxicity scored using CTCAE version 4. Survival analysis was via Kaplan-Meier method, and multivariate Cox proportional hazards modeling was performed. Results: Median age: 60 years. 70% female. T3-T4: 52%. 40% node-positive (N1: 7%, N2: 17%, N3: 16%). Median follow-up: 26 months. At last follow-up, PFS was 79%, CSS was 87%, OS was 81%, and CFS was 88% for the entire cohort. There were no differences in clinical/treatment factors between patients who received 1 cycle MMC (MMC1) vs 2 cycles (MMC2). There was no difference in PFS (HR 0.92, 95% CI 0.41-2.08), CSS (HR 0.36, 95% CI 0.08-1.62), OS (HR 0.73, 95% CI 0.27-2), or CFS (HR 0.91, 95% CI 0.31-2.67) between the MMC1 and MMC2 groups. On multivariate analysis, stage and male gender were predictive of worse PFS, CSS, OS, and CFS. Acute grade ≥2 toxicities for the MMC2 vs MMC1 group were: Skin: 97% vs 84% (p=0.006); Heme: 89% vs 73% (p=0.01); Leukopenia: 86% vs 68% (p=0.01); Neutropenia: 71% vs 53% (p=0.02). There were 3 treatment related deaths, all in the MMC2 group. Conclusions: This study provides evidence that MMC1 results in similar outcomes to MMC2 in patients with anal cancer treated with definitive CRT, with less acute treatment-related toxicity. Randomized trials comparing these 2 regimens could be considered.
USING THE DIABETES COLLABORATIVE REGISTRY (DCR) TO ESTIMATE THE POTENTIAL REAL-WORLD IMPACT OF THE LEADER TRIAL ON IMPROVING CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AT HIGH CARDIOVASCULAR RISK
Authors: Suzanne Arnold, Silvio Inzucchi, Fengming Tang, Darren McGuire, Sanjeev N. Mehta, Abhinav Goyal, Thomas Maddox, Laurence Sperling, Daniel Einhorn, Nathan Wong, Mikhail Kosiborod
Journal: Journal of the American College of Cardiology (2017)
GENOMIC AND PROTEOMIC STUDY OF THE INFLAMMATORY PATHWAY IN PATIENTS WITH ATRIAL FIBRILLATION AND CARDIOMETABOLIC SYNDROME
Authors: Patrick Zakka, Mohammad Karnib, Maria Matar, Sami Bdeir, Moustafa Al Hariri, Mirna Ghemrawi, Jad Ballout, Rami Mahfouz, Ayad Jaffa, Bernard Abi Saleh, Maurice Khoury, Samir Alam, Marwan Refaat
Journal: Journal of the American College of Cardiology (2017)
Tracking JAKs in spondyloarthritis: rationale and expectations
Authors: Corinne Miceli-Richard, Maxime Dougados
Journal: Annals of the Rheumatic Diseases (2017)

In this issue, Van der Heijde and colleagues 1 report the results of a randomised, prospective, placebo-controlled, dose-ranging trial evaluating the short-term (12 weeks) symptomatic effect of a Janus kinase ( JAK) inhibitor, tofacitinib.This well-conducted and optimally presented trial raised two important points: (1) a potential role of the JAK/signal transducer and activator of transcription (STAT) pathway in the pathophysiology of axial spondyloarthritis (SpA) and ( 2) the expected results allowing to anticipate that such compounds might be included in the armamentarium for axial SpA.JAKs are important intracellular tyrosine kinases involved in the signalling of many cytokines, chemokines and growth factors.JAKs play a critical role in both innate and adaptive immunity, which has justified the large number of JAK inhibitors developed in the past decades in the field of cancer but also rheumatology. 1 2 JAKs bind to the intracellular domain of a broad range of receptors.Cytokines binding to their receptor leads to JAK phosphorylation, which allows for recruitment and phosphorylation of STAT protein via their Src Homology 2 domains.STATs then form heterodimers or homodimers that translocate to the nucleus and bind to specific DNA domains, ultimately leading to gene transcription.JAK inhibitors are small molecules that are orally given, an alternative route of administration to subcutaneous-delivered or intravenous-delivered biologics.JAK inhibition is expected to efficiently dampen the inflammation and activation of the immune system observed in several chronic inflammatory conditions such as rheumatoid arthritis, axial SpA, psoriatic arthritis and psoriasis.In contrast to therapeutic antibodies engineered to neutralise one specific cytokine, such as
THREE-DIMENSIONAL ECHOCARDIOGRAPHIC AUTOMATED QUANTIFICATION OF LEFT VENTRICULAR AND ATRIAL VOLUMES USING ADAPTIVE ANALYTICS ALGORITHM: FEASIBILITY IN NON-SELECTED PATIENTS
Authors: Diego Medvedofsky, Lynn Weinert, Isida Byku, Megan Yamat, Eric Kruse, Boguslawa Ciszek, Alma Nelson, Victor Mor-Avi, Roberto Lang
Journal: Journal of the American College of Cardiology (2017)
Meta-analysis of cancer cell lines genomes based on their response to ttfields.
Authors: Moshe Giladi, Yoram Wasserman, Rosa S. Schneiderman, Yaara Porat, Mijal Munster, Uri Weinberg, Eilon David Kirson, Yoram Palti
Journal: Journal of Clinical Oncology (2013)

e22125 Background: Tumor Treating Fields (TTFields) therapy is an established anti-mitotic treatment modality. The inhibitory effect of TTFields was demonstrated in numerous cancer cell lines with some cell lines exhibiting higher treatment sensitivity than others. The goal of the present study is to compare genomic characteristics of cell lines based on their response pattern to TTFields. Methods: Fifteen different human cancerous cell lines were treated using TTFields at their optimal frequency with the same nominal intensity (1.8 V/cm). The distribution of the response to TTFields was found to be bimodal with inhibitions of 30-40% and 50-60% compared to controls. Cell lines were divided into regular and high sensitivity groups according to their response to TTFields. Both groups were characterized based upon the distribution of mutated genes using the Cancer Cell Line Encyclopedia (CCLE) database. Results: Based on the distribution of mutated genes we identified 1 gene with significantly higher probability (P=0.017) to be present in the regular than the high sensitivity group. This gene (NEK3) is a never-in-mitosis (NIMA) related kinase 3 responsible for deacetylation of microtubules. In addition, 2 genes were found with significantly higher probability (P&lt;0.05) to be present in the high- than the regular sensitivity group; ASPH, an aspartate beta-hydroxylase involved in negative regulation of cell proliferation through modulation of calcium homeostasis and TEC, a protein tyrosine kinase involved in immunological signaling pathways. Conclusions: The possible involvement of NEK3 mutations in determining sensitivity to TTFields is interesting in view of the known interference of TTFields with spindle microtubule assembly. ASPH mutations could release cells from negative regulation of proliferation, increasing their replication rate, and thus increasing their sensitivity to TTFields. In order to further test this hypothesis, a comparison of the effect of TTFields needs to be performed on wild type and knockout cell lines for these genes. A comparison of the mutation of these genes in tissue samples from patients whose tumors show high sensitivity to TTFields, may lead to a personalized approach to the use of TTFields clinically.
Evaluation of a lung cancer population in an oncology Medicare advantage program.
Authors: J. Russell Hoverman, Marcus A. Neubauer, Jad Hayes, Kathryn Eagye, Melissa Jameson, Amy Supraner, Maria Sipala, Vanessa Torres, Michael A. Kolodziej
Journal: Journal of Clinical Oncology (2015)

e19117 Background: A recent report identifies hospitalization as the principal driver of both cost and regional variation in advanced cancer. Understanding risks for inpatient admission (IPA) would help guide treatment planning, reducing variation and cost. Herein we report baseline data for Medicare age lung cancer patients (pts) in the Innovent Oncology disease management program (IO) for those with and without an IPA. Methods: Aetna MA pts with lung cancer treated with chemotherapy (chemo) at Texas Oncology and managed by IO from 6/2013 to 9/2014 (n=75) were eligible for this cohort study, and were divided into 2 groups: had an IPA after Cycle 1, Day 1 (C1D1) of chemo or did not. Characteristics and outcomes were obtained from claims and EHR data and compared by χ2and Wilcoxon Rank Sum tests (α = .05). Results: Results are in Table 1. There are no significant differences in age, sex, histology, stage at presentation, line of therapy, or performance status. Ptswith IPAs had more deaths. 40 patients had 69 IPAs. 40% of initial IPAs were chemo related: 23 % within 14 days of C1D1, 18% in days 15-30 and 60% after 30 days. 73% getting combined chemo/radiation had an IPA. Numbers were too small to identify a dominant IPA cause. Conclusions: There were both early and late effects of chemo associated with IPAs. Ptswith combined therapy are at high risk. These are 15 months results in a three year study. Continued enrollment will help us further characterize the high hospitalization burden in this population to help stratify risk. Did Not Have an IPA Had an IPA (n=35) (n=40) p-value (No., % of total) or (Median [Min, Max]) Demographics Female (16, 47.7%) (19, 47.5%) 0.88 Age 72.4 [63.6, 88.3] 73.3 [66.0, 90.8] 0.85 Disease Factors Diagnosis 0.78 NSCLC 28, 80.0% 33, 82.2% SCLC 7, 20.0% 7, 17.5% Stage at Diagnosis 0.42 I 2, 8.8% 1, 2.5% II 2, 5.0% III 16, 47.7% 15, 37.5% IV 16, 45.7% 21, 52.5% Unknown 1, 2.5% Metastatic 27, 77.1% 33, 82.5% 0.57 LOT > 2 7, 20.0% 3, 7.5% 0.17 KPS > 80% 27, 77.1% 31, 77.5% 0.97 Outcomes Deceased 10, 28.6% 21, 52.5% 0.04 Entered Hospice 8, 22.9% 8, 20.0% 0.76 Days in Hospice 8.0 [1, 68] 6.5 [3, 49] 1.000
THE CONTRAST VOLUME TO CREATININE CLEARANCE RATIO PREDICTS CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Xiaosheng Guo, Jiyan Chen, Yong Liu, Ning Tan, Yingling Zhou, Weijie Bei, Hualong Li, Shiqun Chen, Liwen Li
Journal: Journal of the American College of Cardiology (2017)
Powerful Risk Stratification in Patients with AL Using Serum Cardiac Biomarkers.
Authors: Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Robert A. Kyle, Shaji K. Kumar, Mark R. Litzow, Dennis A. Gastineau, David J. Inwards, Ivana N. Micallef, Michelle A. Elliott, Luis F. Porrata, William J. Hogan, Patrick B. Johnston, Morie A. Gertz
Journal: Blood (2005)
Human CMVpp65-Specific Stem Cell-like Memory T-Cells (TSCM) Are a Principal Source for Rapid Repopulation of Immunodominant Central Memory (TCM) and Effector Memory (TEM) in the Circulation
Authors: Tzu-Yun Kuo, Aisha Hasan, Manuel Guerreiro, Richard J. O'Reilly
Journal: Blood (2016)
PREDICTORS OF ISCHEMIC EVENTS WITHIN AND AFTER 1 YEAR AFTER AN ACUTE CORONARY SYNDROME: RESULTS FROM THE EPICOR REGISTRY
Authors: Uwe Zeymer, Xavier Rossello, Stuart J. Pocock, Frans Van de Werf, Nicolas Danchin, Lieven Annemans, Jesús Medina, Héctor Bueno
Journal: Journal of the American College of Cardiology (2017)
Time to treatment (TTT) and breast cancer survival in the United States.
Authors: Richard J. Bleicher, Karen Ruth, Elin R. Sigurdson, J. Robert Beck, Eric A. Ross, Yu-Ning Wong, Sameer A. Patel, Marcia Boraas, Eric I. Chang, Neal S. Topham, Brian L. Egleston
Journal: Journal of Clinical Oncology (2015)

6575 Background: Time to initiate breast cancer treatment is increasing in the United States, but controversy surrounds the impact of TTT on survival. The impact of the interval between diagnosis and treatment is a source of concern to patients and clinicians. We investigated the relationship using separate analyses of two of the largest cancer databases in the United States. Methods: Patients had noninflammatory, nonmetastatic, invasive breast cancer, with surgery as initial treatment. The first study used the SEER-Medicare database (SMDB), and second, the National Cancer Database (NCDB). Each analysis assessed survival as a function of time between diagnosis and operation ( ≤ 30, 31-60, 61-90, 91-120, and 121-180 days [d] from diagnosis), adjusting for demographics, comorbidities, tumor-related factors, and treatment. Results: The SMDB cohort had 94,544 patients ≥ 66 years old, diagnosed between 1992 and 2009. With each interval delay increase, adjusted overall survival (OS) was lower for all patients (hazard ratio [HR] 1.09, p< 0.001), and for those having stage I (hazard ratio [HR] 1.13, p< 0.001) and stage II (HR 1.06, p= 0.010) disease. Breast cancer-specific mortality increased with each 60-d interval (subhazard ratio 1.26, p= 0.03). The NCDB study evaluated 115,790 patients ≥ 18 years old, diagnosed between 2003 and 2005. The adjusted overall mortality HR was 1.10 (p< 0.001) for each increasing interval, significant in stages I (HR 1.16, p< 0.001) and II (1.09, p< 0.001) disease. Five-year OS adjusted for demographics, comorbidities, tumor-related factors and treatment in the SMDB progressively declined from 78.1% for ≤ 30 d to 60.9% for 121-180 d and in the NCDB from 88.0% for ≤ 30 d to 80.4% for 121-180 d. Conclusions: Independent analyses of two national cohorts demonstrate that an increased time to initiate surgical treatment confers lower overall and disease-specific survival for patients with early stage breast cancer. A shortened delay is associated with an outcome benefit comparable in magnitude to the addition of some standard therapies. Although time is required for preoperative evaluation and consideration of options such as reconstruction, efforts to reduce TTT should be pursued where possible to enhance survival.
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Authors: Roy M Pollock, Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Christina R Majer, Jeffrey Song, Christina J Allain, Christopher J Sneeringer, L. Danielle Johnston, Margaret Porter Scott, Lei Jin, Kevin W Kuntz, Richard Chesworth, Mikel P Moyer, Kathrin M Bernt, Scott Armstrong, Robert A Copeland, Victoria M Richon
Journal: Blood (2010)
Risk factors for melanoma among survivors of non-Hodgkin lymphoma in the U.S. elderly population.
Authors: Clara JK Lam, Rochelle E Curtis, Graca Dores, Eric A. Engels, Neil Caporaso, Aaron Polliack, Heather A. Young, Paul H. Levine, Angelo F Elmi, Joseph F. Fraumeni, Margaret A. Tucker, Lindsay M. Morton
Journal: Journal of Clinical Oncology (2014)

1533 Background: Non-Hodgkin lymphoma (NHL) survivors have increased risk of developing melanoma compared with the general population. Although immune dysfunction may play a role, no previous study has investigated immune-related factors and melanoma risk after NHL. Methods: We used the SEER-Medicare linkage to identify a cohort of 44,875 individuals who were diagnosed with first primary NHL during 1992-2009 at ages 65-84 years and survived ≥1 year. Cox regression quantified melanoma risk associated with NHL treatments as well as autoimmune conditions and infections occurring at age ≥65. Results: A total of 202 second primary melanomas occurred during 248,917 person-years, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes. Melanoma risk after CLL/SLL was significantly increased among patients who received fludarabine- and rituximab-containing chemotherapy (hazard ratio [HR]=2.99, 95% confidence interval [CI]=1.68-5.33, versus no chemotherapy), whereas risk was not evident for rituximab-containing therapy without fludarabine. Among non-CLL/SLL patients, melanoma risk was significantly elevated for patients receiving cyclophosphamide-containing chemotherapy without rituximab (HR=2.15, 95%CI=1.26-3.65) or rituximab and cyclophosphamide-containing chemotherapy (HR=1.66, 95%CI=1.00-2.75). Occurrence of autoimmune diseases after NHL diagnosis was associated with increased risk of melanoma (B-cell activating diseases: HR=1.43, 95% CI=1.02-2.01; T-cell activating diseases: HR=1.39, 95%CI=0.94-2.04), with particularly elevated risks for asthma occurring after CLL/SLL (HR=2.11, 95%CI=1.09-4.08). In contrast, localized scleroderma was associated with increased melanoma risk both prior to (HR=1.47, 95% CI=1.00-2.16) and after NHL (HR=1.44, 95%CI=0.87-2.39). Similarly, urinary tract infection was associated with increased melanoma risk prior to (HR=1.39, 95%CI=0.99-1.94) and after NHL (HR=1.59, 95%CI=1.05-2.41), but no significant associations were observed for other infections. Conclusions: These findings support a role for immune perturbation in the development of melanoma after NHL.
Laparoscopic transgastric circumferential stapler-assisted vs. endoscopic esophageal mucosectomy in a porcine model
Authors: Daniel Steinemann, Andreas Zerz, Philip Müller, Peter Sauer, Anja Schaible, Felix Lasitschka, Anne-Catherine Schwarz, Beat Müller-Stich, Georg Linke
Journal: Endoscopy (2017)

Background and study aims Extensive endoscopic mucosal resection (EMR) for Barrett's esophagus (BE) may lead to stenosis. Laparoscopic, transgastric, stapler-assisted mucosectomy (SAM) with the retrieval of a circumferential specimen is proposed. Methods SAM was evaluated in two phases. The feasibility of SAM and the quality of specimens were assessed in eight animals. The mucosal healing was evaluated in a 6-week survival experiment comparing SAM (n = 6) with EMR (n = 6). The ratio of the esophageal lumen width (REL) at the resection level measured on fluoroscopy at 6 weeks divided by the width immediately after resection was compared. Results In all animals, a circular mucosectomy specimen was successfully obtained, with a median area of 492 mm2 (interquartile range [IQR] 426 - 573 mm2) and 941 mm2 (IQR 813 - 1209 mm2) using a 21 mm and 25 mm stapler, respectively. In the survival experiments, symptomatic stenosis developed in two animals after EMR and in none after SAM. The REL was 0.27 (0.18 - 0.39) and 0.96 (0.9 - 1.04; P < 0.0001) for EMR and SAM, respectively. Conclusions SAM provides a novel technique for en bloc mucosectomy in BE. In contrast to EMR, mucosal healing after SAM was not associated with stenosis up to 6 weeks after intervention.
NAILFOLD CAPILLAROSCOPY FOR THE IDENTIFICATION OF MICROVASCULAR DISEASE IN AFRICAN-AMERICANS
Authors: Muhammad Afzal Khan, Venu Pasricha, Steven Song, Mahyar Pourriahi, Muhammad Ihsan, Arismendy Nunez Garcia, Attiya Haque, Allan Bowen, Louis Salciccioli, Jason Lazar
Journal: Journal of the American College of Cardiology (2017)
Circular RNAs of the Nucleophosmin 1 (NPM1) Gene in Acute Myeloid Leukemia Patients
Authors: Susanne Hirsch, Tamara J. Blätte, Sarah Grasedieck, Arefeh Rouhi, Mojca Jongen-Lavrencic, Florian Kuchenbauer, Peter Paschka, Verena I. Gaidzik, Konstanze Döhner, Sibylle Cocciardi, Anna Dolnik, Lars Bullinger
Journal: Blood (2016)
PREVALENCE AND RISK FACTORS ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN PATIENTS WITH SINGLE VENTRICLE CONGENITAL HEART DISEASE AFTER FONTAN PALLIATION
Authors: Sheetal Patel, David Kwiatkowski, Adin-Cristian Andrei, Ankita Devareddy, Catherine Krawczeski, Barbara J. Deal, Craig Langman, Bradley Marino
Journal: Journal of the American College of Cardiology (2017)
LEFT VENTRICULAR FILLING RATE PREDICTS CLINICAL FAILURE IN PATIENTS WITH PRECAPILLARY PULMONARY HYPERTENSION
Authors: George Giannakoulas, Sofia Mouratoglou, Vasileios Kamperidis, Georgia Pitsiou, Alexandros Kallifatidis, Stavros Hadjimiltiades, Haralampos Karvounis
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF THE EFFECTS OF BALLOON EXPANDABLE AND SELF EXPANDABLE TRANSCATHETER AORTIC VALVE REPLACEMENT ON THE DIMENSIONS OF THE MITRAL VALVE ANNULUS AND MITRAL REGURGITATION SEVERITY
Authors: Joseph Burke, Ernesto Salcedo, Tamas Seres, Robert Quaife, Paola Roldan, Esra Donmez, John Messenger, John Carroll
Journal: Journal of the American College of Cardiology (2017)
HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Ibadete Bytyci, Gani Bajraktari, Deepak L. Bhatt, Charity J. Morgan, Ali Ahmed, Wilbert S. Aronow, Maciej Banach
Journal: Journal of the American College of Cardiology (2017)
Kdm6b regulates cartilage development and homeostasis through anabolic metabolism
Authors: Jun Dai, Dongsheng Yu, Yafei Wang, Yishan Chen, Heng Sun, Xiaolei Zhang, Shouan Zhu, Zongyou Pan, Boon Chin Heng, Shufang Zhang, Hongwei Ouyang
Journal: Annals of the Rheumatic Diseases (2017)

Epigenetic mechanisms have been reported to play key roles in chondrogenesis and osteoarthritis (OA) development. Here, we sought to identify specific histone demethylases that are involved and delineate the underlying mechanisms.We screened the expression of 17 distinct histone demethylases by quantitative real time PCR (qRT-PCR) during chondrogenic differentiation of C3H10T1/2 cells. The role of Kdm6b in cartilage development was then analysed with transgenic Col2a1-CreERT2;Kdm6bf/f . RNA-Seq was applied to explore the underlying changes in chondrocytes upon knockdown of Kdm6b. Experimental OA in mice was induced by destabilisation of the medial meniscus in C57BL/6J (wild type, Kdm6bf/f and Col2a1-CreERT2;Kdm6bf/f ) mice, either with intra-articular injection of shKdm6b lentivirus or after tamoxifen treatment. Mouse joints and human cartilage samples were used for histological analysis.Kdm6b expression was significantly increased during cartilage development. Col2a1-CreERT2;Kdm6bf/f mice displayed obvious skeletal abnormalities at E16.5 and E18.5 with intraperitoneal injection of tamoxifen at E12.5. RNA-Seq and qRT-PCR analyses revealed decreased expression of chondrocyte anabolic genes in Col2a1-CreERT2;Kdm6bf/f chondrocytes. The histological OA score was significantly higher in mice injected with Kdm6b short hairpin RNA lentivirus. Col2a1-CreERT2;Kdm6bf/f mice exhibited accelerated OA development at 8 and 12 weeks following surgical induction. The number of Kdm6b-positive chondrocytes was lower in both mice and human OA cartilage samples.These findings indicate that knockdown of Kdm6b in chondrocytes leads to abnormal cartilage development and accelerated OA progression via inhibition of the anabolic metabolism of chondrocytes. Understanding the epigenetic mechanism of joint cartilage development and homeostasis would be useful for development of new therapeutic modalities for OA.
REDUCTION IN INTERSTAGE GROWTH FAILURE IN INFANTS WITH HYPOPLASTIC LEFT HEART SYNDROME AND IMPACT ON STAGE 2 OUTCOMES: A REPORT FROM THE NATIONAL PEDIATRIC CARDIOLOGY QUALITY IMPROVEMENT COLLABORATIVE
Authors: Jeffrey B. Anderson, David Brown, Megan Horsley, Katherine Bates, Samuel Hanke, Stacey Lihn, James Tweddell, Carole Lannon
Journal: Journal of the American College of Cardiology (2017)
THREE-YEAR RESULTS FROM THE EVOLVE II RANDOMIZED TRIAL: LATE CLINICAL OUTCOMES WITH BIORESORBABLE COMPARED TO PERMANENT POLYMER EVEROLIMUS-ELUTING
Authors: Dean J. Kereiakes, Ian Meredith, Stephan Windecker, Josep Rodes-Cabau, Tommy Lee, Arthur Reitman, Andrejs Erglis, Mark Dorogy, Barry Bertolet, Louis Cannon, Juhani Airaksinen, Craig Siegel, Thomas Christen, Dominic Allocco, Keith Dawkins
Journal: Journal of the American College of Cardiology (2017)